Evidence map›Paper›PMID 41003134›Full record

ReviewJournal of personalized medicine2025

Metabolic Signature of

Cristina Banella, Gianfranco Catalano, Maura Calvani, Eleonora Candi, Nelida Ines Noguera, Serena Travaglini

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cristina BanellaDepartment of Pediatric Hematology-Oncology, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
Gianfranco CatalanoDepartment of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.
Maura CalvaniDepartment of Pediatric Hematology-Oncology, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.ORCID 0000-0003-0750-4706
Eleonora CandiDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Nelida Ines NogueraDepartment of Biomedicine and Prevention, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0001-7682-862X
Serena TravagliniDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-5411-1502

Funding

Italian Association for Cancer Research DR3392Ministero dell'università e della ricerca M4C2I1.3
6 · The paper itself

Abstract

Acute Myeloid Leukemia (AML) is a genetically and clinically heterogeneous malignancy marked by poor prognosis and limited therapeutic options, especially in older patients. While conventional treatments such as the "7 + 3" chemotherapy regimen and allogeneic stem cell transplantation remain standard care options, the advent of next-generation sequencing (NGS) has transformed our understanding of AML's molecular complexity. Among the emerging hallmarks of AML, metabolic reprogramming has gained increasing attention for its role in supporting leukemic cell proliferation, survival, and therapy resistance. Distinct AML subtypes-shaped by specific genetic alterations, including

Indexed as

Acute Myeloid LeukemiaFLT3-ITDmetabolic plasticitymetabolic targeting

Identifiers

PMID41003134
PMCPMC12470870

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.